Therakind
UK-based specialty pharmaceutical company focused on improving medicine adherence through reformulation, device-enabled delivery and partnership development. The company develops and co-develops dry powder intranasal delivery platforms and dry-powder formulations, offers feasibility/proof-of-concept services for partner candidates, holds multiple device patents, and has previously obtained marketing authorisations for three products across major regulators.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Oral methotrexate solution (marketed product)
Palatable 2 mg/mL oral methotrexate solution formulation indicated for rheumatological disorders, juvenile idiopathic arthritis and certain oncology indications; marketed in multiple territories and previously subject to regional licensing and distribution agreements.
Dry powder intranasal delivery platform
A platform of dry powder intranasal device formats (single-dose and reusable multi-dose cartridges) designed to deliver small molecules, peptides, proteins and vaccines without needles and with potential for extended shelf life.
reusable with disposable
A reusable nasal powder device utilizing prefilled disposable nosepieces where the plunger is pushed to release the dry powder drug.
Reusable device with disposable cartridges
A reusable nasal powder device utilizing prefilled disposable cartridges placed into the device body.
DriDose Multi-dose Cartridge
A reusable nasal powder delivery device with disposable cartridges pre-filled with drug, enabling simple self-administration without specialist training or coordination of breathing.
Ready-to-use device prefilled with the drug
A ready-to-use device prefilled with the drug where the nosepiece is placed in the nostril and the plunger is pushed to release dry powder into the nasal cavity.
Oral methotrexate solution (marketed product)
Palatable 2 mg/mL oral methotrexate solution formulation indicated for rheumatological disorders, juvenile idiopathic arthritis and certain oncology indications; marketed in multiple territories and previously subject to regional licensing and distribution agreements.
Dry powder intranasal delivery platform
A platform of dry powder intranasal device formats (single-dose and reusable multi-dose cartridges) designed to deliver small molecules, peptides, proteins and vaccines without needles and with potential for extended shelf life.
reusable with disposable
A reusable nasal powder device utilizing prefilled disposable nosepieces where the plunger is pushed to release the dry powder drug.
Reusable device with disposable cartridges
A reusable nasal powder device utilizing prefilled disposable cartridges placed into the device body.
DriDose Multi-dose Cartridge
A reusable nasal powder delivery device with disposable cartridges pre-filled with drug, enabling simple self-administration without specialist training or coordination of breathing.
Ready-to-use device prefilled with the drug
A ready-to-use device prefilled with the drug where the nosepiece is placed in the nostril and the plunger is pushed to release dry powder into the nasal cavity.
Services
Reformulation, characterisation and early-stage compatibility testing of partner drug candidates for dry powder intranasal administration.
Joint development of dry powder nasal formulations and device-configured delivery options including single-use and reusable multi-dose cartridges.
Out-licensing and distribution arrangements for marketed products and negotiated partnerships for regional commercialisation.
Support for regulatory planning and preparation of development packages informed by prior marketing authorisations and device validation data.
Reformulation, characterisation and early-stage compatibility testing of partner drug candidates for dry powder intranasal administration.
Joint development of dry powder nasal formulations and device-configured delivery options including single-use and reusable multi-dose cartridges.
Out-licensing and distribution arrangements for marketed products and negotiated partnerships for regional commercialisation.
Support for regulatory planning and preparation of development packages informed by prior marketing authorisations and device validation data.
Expertise Areas
- Intranasal drug delivery
- Dry powder formulation development
- Device-based combination product development
- Powder filling and cartridge engineering
Key Technologies
- Dry powder intranasal delivery
- Multi-dose cartridge systems
- Reusable nasal device design
- Spray-drying for powder formulations
News & Updates
Strategic partnership to support device industrialisation and broaden manufacturing and formulation expertise for dry powder intranasal delivery.
Awarded grant funding to support formulation development and feasibility studies of an antiemetic candidate for dry powder nasal delivery and to build a data package for multi-dose cartridge delivery.
United States patent granted for a multi-dose, needle-free dry powder nasal delivery mechanism; part of a wider international patent portfolio for device variants.
Sale of non-US rights for the company's oral methotrexate solution to a regional specialty pharma partner as part of a strategy to focus on nasal delivery platform development.
Preclinical study demonstrated that dry powder intranasal delivery produced comparable serum antibody responses to a standard applicator in an animal model with no detectable adverse effects.
Strategic partnership to support device industrialisation and broaden manufacturing and formulation expertise for dry powder intranasal delivery.
Awarded grant funding to support formulation development and feasibility studies of an antiemetic candidate for dry powder nasal delivery and to build a data package for multi-dose cartridge delivery.
United States patent granted for a multi-dose, needle-free dry powder nasal delivery mechanism; part of a wider international patent portfolio for device variants.
Sale of non-US rights for the company's oral methotrexate solution to a regional specialty pharma partner as part of a strategy to focus on nasal delivery platform development.
Preclinical study demonstrated that dry powder intranasal delivery produced comparable serum antibody responses to a standard applicator in an animal model with no detectable adverse effects.